European Launch of ResistancePlus MG FleXible for the GeneXpert System
16.12.2019 10:00:00 EET | Business Wire | Press release
SpeeDx Pty, Ltd. today announced the European launch of Resistance Plus® MG FleXible, the first sample-to-answer test for detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance. Cepheid is the exclusive distribution partner of this test, available through Cepheid’s FleXible Cartridge programme for the GeneXpert System.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005039/en/
ResistancePlus MG FleXible is now selling in France and the U.K. (to be followed by rest of EU, Australia and New Zealand). This successful collaboration between SpeeDx and Cepheid is the first sample-to-answer test for Mgen and macrolide resistance - exclusively distributed by Cepheid. (Photo: Business Wire)
Management guidelines around the world, including those recently updated in France1 and the U.K.2, reference testing the macrolide resistance status of Mgen infections in order to more effectively treat patients. Mgen can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease, and has been linked to reproductive health complications including pre-term birth and infertility.2,3 Due to the challenges of rising antimicrobial resistance and a lack of clear data that asymptomatic infection leads to protracted health complications, Mgen testing guidelines are unanimous in their recommendation to only test symptomatic individuals.
“This is an important test expansion for the thousands of GeneXpert Systems on the market,” said Colin Denver, SpeeDx CEO. “ Resistance Plus MG FleXible enables Resistance Guided Therapy, supporting more clinicians to adhere to testing guidelines and maximising effective care for their patients infected with Mgen.”
Both SpeeDx and Cepheid will be showcasing Resistance Plus MG at RICAI (Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse) December 15th and 16th in Paris. Visit SpeeDx booth #41bis and Cepheid booth #18 to learn more.
About SpeeDx
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. The SpeeDx Resistance Plus® MG open-platform assay is CE marked for sale in Europe, TGA approved for sale in Australia and clinical trials are being finalised for submission to the U.S. FDA. Products in the SpeeDx portfolio focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
For more information on SpeeDx please see: https://plexpcr.com
- https://www.sfdermato.org/site/groupe-infectiologie-dermatologique-et-infections-sexuellement-transmissibles.html
- https://www.bashhguidelines.org/media/1146/ngu-update-05_2017-final.pdf
- http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191215005039/en/
Contact information
SpeeDx:
Europe, Australia, New Zealand:
Madeline O’Donoghue
+61 2 9209 4170
madelineo@speedx.com.au
Cepheid:
Darwa Peterson
darwa@cepheid.com
Tel. + 1.408.400.4324
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carrier and PHINIA Recognized with ISG Paragon Awards North America 2026 for Transformation Delivered with LTM30.9.2026 11:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that its clients PHINIA and Carrier have been recognized at the ISG Paragon Awards North America 2026. LTM received recognition in the Excellence category for its work with PHINIA and in the Transformation category for its work with Carrier. The ISG Paragon Awards recognize enterprise-provider partnerships that leverage technology, innovation, and new operating models to deliver measurable business impact. The recognitions highlight LTM's ability to help global enterprises accelerate transformation through industry expertise, technology innovation, and execution excellence. Carrier: Following significant M&A activities, Carrier, a global leader in intelligent climate and energy solutions, sought to address a fragmented technology landscape, siloed operating functions, and limited visibility into application ownership and costs across its 2,000+ application estate. LTM partnered closely with Carrier
RGI Expands Its Digital Insurance Proposition With the Acquisition of D4Next30.9.2026 11:00:00 EEST | Press release
RGI, the leading provider of digital solutions for the European insurance industry, announces the acquisition of D4Next, an insurance technology company specializing in solutions that connect insurance products, distribution channels and digital processes, powered by innovative AI models. The acquisition broadens RGI’s ability to support insurers in addressing one of the key challenges facing the industry: how to accelerate business and technological innovation while progressively evolving an increasingly complex technology landscape. Supporting the evolution of insurance at the pace of the market As insurers continue to invest in new products, digital channels, distribution models and more intelligent processes, the ability to introduce innovation progressively, and connect new capabilities with the technologies already supporting the business, is becoming increasingly important. With the acquisition of D4Next, RGI expands its proposition with capabilities designed to support this evo
Roquette to Showcase End-to-End Pharma Solutions for Patient-Centric Formulations at CPHI Milan 202630.9.2026 11:00:00 EEST | Press release
Roquette will showcase its end-to-end portfolio of pharmaceutical excipients, drug delivery solutions and leading technical expertise at CPHI Milan 2026 in Italy, where the company will welcome visitors at booth 1A18 in the excipients hall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929017969/en/ Visit Roquette at booth 1A18 in the excipients hall. At this year’s global industry event, Roquette will highlight key product brands supporting formulation performance, patient-centric drug delivery and biopharma innovation, including METHOCEL™ cellulose ethers, PEARLITOL® mannitol, Avicel® microcrystalline cellulose, POLYOX™ polyethylene oxide, KLEPTOSE® cyclodextrins, LYCADEX® pyrogen-free dextrose monohydrate, Qualicaps™ by Roquette hard capsules and its alginate portfolio from sustainably sourced seaweed. The company will also spotlight its biopharma solutions spanning upstream processing, downstream efficiency, and form
SoftBank Robotics Expands AI & Robotics Solutions for Foodservice in EMEA30.9.2026 10:30:00 EEST | Press release
SoftBank Robotics UK Ltd. today announced that it will showcase its AI & Robotics solutions for foodservice at EquipHotel 2026, taking place in Paris, France, from 2 to 5 November 2026, as part of its efforts to expand foodservice automation initiatives across the EMEA region. Hospitality and foodservice operators continue to face operational challenges, including labour shortages, difficulties in recruiting skilled staff, rising costs, inconsistent food quality, and food waste. SoftBank Robotics aims to help address these challenges through robotics and automation, supporting more efficient, consistent and flexible foodservice operations. STEAMA is a steam-based cooking robot that uses high-pressure, high-temperature steam to prepare frozen noodle dishes in about 90 seconds. Designed for simple, one-touch operation, it helps operators consistently serve freshly prepared dishes with ease. FLAMA and BOTINKIT Omni are automated cooking solutions that improve kitchen efficiency and consis
IFF Introduces AQUASCENT™: Advanced Water-Based Fragrance Technology30.9.2026 10:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances and health and biosciences, today introduced AQUASCENT™, a new vegan, water-based carrier for fine fragrance. Crafted from a proprietary formula made with biodegradable materials, AQUASCENT™ delivers enhanced olfactive performance and visual clarity for consumers while supporting a more sustainable approach to shipping the product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929938674/en/ AQUASCENT™ is IFF's new water-based fragrance carrier technology that maintains visual clarity while supporting fragrance loads from 10% to up to 25%, compared with up to 15% for most comparable systems. “AQUASCENT™ reflects our continued investment in new scent technologies and formats that create compelling fragrance experiences while supporting the industry’s growing focus on sustainability,” said Sabrya Meflah, president of Fine Fragrance for IFF Scent. “This technology illus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom